Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Department of Therapeutic Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
In Vivo. 2020 Mar-Apr;34(2):897-902. doi: 10.21873/invivo.11855.
Concurrent chemoradiotherapy (CCRT) is the gold standard for limited-stage small-cell lung cancer (LS-SCLC); however, most patients inevitably experience relapse. We hypothesized consolidation amrubicin following CCRT to be a potential treatment for LS-SCLC.
All enrolled patients were treated using induction CCRT consisting of four cycles of etoposide and cisplatin plus concurrent thoracic radiotherapy. Eligible patients then received three cycles of amrubicin as consolidation therapy (consolidation population). The primary endpoint was the 2-year progression-free survival rate in the consolidation population.
Of the 36 intention-to-treat patients, 28 (78%) received amrubicin and 24 (67%) completed all planned treatments. The 2-year progression-free survival rate and overall response rate were 35.7% and 86%, respectively. The median progression-free and overall survival were 14.3 and 60.9 months, respectively. There were no treatment-related deaths in the intention-to-treat population.
This study was terminated due to slow patient accrual; however, this treatment strategy was feasible and demonstrated promising efficacy.
同期放化疗（CCRT）是局限期小细胞肺癌（LS-SCLC）的金标准；然而，大多数患者不可避免地会复发。我们假设 CCRT 后进行巩固性氨柔比星治疗可能是 LS-SCLC 的一种潜在治疗方法。
所有入组患者均接受包含 4 个周期依托泊苷和顺铂联合胸部放疗的诱导性 CCRT。符合条件的患者随后接受 3 个周期的氨柔比星作为巩固治疗（巩固组）。主要终点是巩固组的 2 年无进展生存率。
在 36 例意向治疗患者中，28 例（78%）接受了氨柔比星治疗，24 例（67%）完成了所有计划的治疗。2 年无进展生存率和总缓解率分别为 35.7%和 86%。中位无进展生存期和总生存期分别为 14.3 个月和 60.9 个月。意向治疗人群中无治疗相关死亡。
由于患者入组缓慢，本研究提前终止；然而，这种治疗策略是可行的，且疗效有一定潜力。
